Biolinerx vs Longeveron
Biolinerx and Longeveron are similar in size: $1.2m and $1.2m of revenue in their latest fiscal years. Longeveron grew faster (-49.9% against -95.9%). Biolinerx kept more of each dollar of sales as profit: a net margin of -171.7% against -1893.6%. Biolinerx carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | BiolinerxBLRX, 2025 | LongeveronLGVN, 2025 |
|---|---|---|
| Revenue | $1.2m | $1.2m |
| Revenue growth | -95.9% | -49.9% |
| Net income | −$2.0m | −$22.7m |
| Operating margin | -871.8% | -1942.2% |
| Net margin | -171.7% | -1893.6% |
| Return on equity | -12.8% | -164.7% |
| Free cash flow | −$8.1m | −$18.9m |
| Cash | $3.3m | $4.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 37 |
| Market value | $8.1m | $53.7m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |